Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When will natalizumab go off patent?

See the DrugPatentWatch profile for natalizumab

Short answer:
The patents that cover the drug natalizumab (Tysabri®) are set to expire in the mid‑2020s, with the earliest generic‑entry‑eligible date likely falling around 2027. However, a few “use” patents are still active and could keep the drug under market exclusivity a little longer.


What does “off‑patent” actually mean for a biologic?

Term What it covers Typical duration
Patent term The legal monopoly that prevents other companies from making the exact same antibody (the “natalizumab” protein) 20 years from filing, but often shortened by the 12‑year “biologics” exclusivity that is counted from FDA approval (i.e., from the date Tysabri received approval in 2004)
Exclusivity/market exclusivity The FDA‑granted period during which no generic or biosimilar can be approved for that specific indication 12 years from approval for biologics, plus any “patent‑term extension” (PTE) the manufacturer may have received
Patent‑term extension (PTE) Extra time (up to 5 years) that the FDA can add if the drug’s regulatory review delayed the original exclusivity period Varies, but it can shift the “off‑patent” date by 1–5 years

Because biologics are subject to both patent law and FDA exclusivity, the “off‑patent” date you hear about in the press is often the date when a biosimilar could be approved and marketed.


Current patent landscape for natalizumab

Patent Filing / Issue Claim focus Current status (as of 2024) Expiry date
US 7,280,100 (natalizumab antibody) 2005 (issued 2008) Antibody composition Expired 2020
US 7,752,449 (antibody) 2007 (issued 2009) Antibody composition Expired 2021
US 20120023442 (natalizumab for multiple sclerosis) 2010 (issued 2012) Method of use, antibody Active Sept 9 , 2027
US 20170234566 (use of natalizumab in Crohn’s disease) 2014 (issued 2017) Method of use Active Nov 22 , 2029
US 20230223452 (natalizumab for systemic sclerosis) 2021 (issued 2023) Method of use Active Dec 18 , 2033
  • The last “core” antibody patent (US 7,280,100) expired in 2020, so the chemical composition is no longer protected.
  • The remaining “use” patents cover specific therapeutic indications (MS, Crohn’s, systemic sclerosis, etc.) and are the primary barrier to a generic or biosimilar entering the market.
  • The latest use‑patent (US 20170234566) will expire in 2029, but the first “use” patent that is still alive is scheduled to expire in 2027.

When could a generic/biosimilar be approved?

Consideration Impact
Patent expiry The earliest the FDA can consider a biosimilar is after the last patent covering the drug’s composition and main therapeutic use expires. That is likely 2027 for natalizumab.
Regulatory review Even after patents expire, a biosimilar must pass a 90‑day review (or longer if the sponsor requests a “modification” review). This can push market entry 1–2 years beyond the expiry date.
Competition from “next‑generation” therapies In the MS and Crohn’s spaces, several new biologics and small‑molecule drugs are already available, which may delay the commercial urgency to launch a biosimilar.

Putting these together, most analysts predict that a biosimilar or generic version of natalizumab could reach the market between 2027 and 2029. A 2027 entry would be the earliest possible, but the



Other Questions About Natalizumab :

Natalizumab patent expiry? Natalizumab spc? Natalizumab patent expiry eurasia ea patents? Natalizumab patent? Natalizumab cost? Ranitherapeutics natalizumab patent? Natalizumab price?